In general, levodopa inhibited the growth of ESCC cells through regulating pathways involved in oxidative phosphorylation, NAFLD, and Parkinson disease, down-regulating the levels of SDHD, NDUFS4, and MT-CO3, and inhibiting oxidative phosphorylation. The gene discussed is SDHD; the disease is metabolic dysfunction-associated steatotic liver disease.